Browse Articles
Discover research articles across all indexed journals
Developing a nomogram for risk prediction of the low T3 syndrome
A liquid biopsy-based proteomic assay to identify circulating tumor cell (CTC) –derived druggable targets in cancer patients.
258 Background: Cancers are often thought of as a disease of a specific tissue; however, the drugs designed to fight them are tissue agnostic. These drugs function by typically targeting mutant or amplified proteins such as kinases, transcription factors, or other cell surface proteins. An ever-growing body of research shows that many well characterized protein targets are commonly found across many cancer types and can serve as potential targets for pan-cancer therapies. Despite this, enrollment criteria for clinical trials often do not include any test to measure the presence of a particular protein drug target, and almost universally do not attempt to quantify the target. As a result, patient-specific protein profiles should be utilized to not only minimize patient harm but to categorize patients so that drug trials can be more intentional in identifying only the patients most likely to benefit from a selected drug. To that end, we developed a liquid biopsy-based proteomic assay to measure multiple proteins of interest simultaneously from enriched circulating tumor cells (CTCs) in blood and to detect druggable protein targets. Methods: CTCs were isolated using Astrin Bioscience’s proprietary enrichment system yielding matched CTC and white blood cell (WBC) fractions. Samples were then processed in parallel following a custom developed protein aggregation capture protocol followed by trypsin digestion to yield peptide samples for bottom-up targeted peptide analysis by mass spectrometry on a FAIMS equipped Exploris 480 instrument. Results: We prospectively enrolled 20 heavily-pretreated metastatic castration resistant prostate cancer (mCRPC) patients from whom matched CTC and WBC profiles were analyzed. The median age of these patients was 74 years, 80% had Gleason GG4-5, 30% had visceral metastases, median number of prior systemic therapies was 5, and median PSA level was 135 ng/mL. The mean CTC count was 10.4 cells/mL with a median of 4.9 CTCs/mL. After CTC enrichment, we observed vastly diverse intra- and inter-patient proteomic profiles. Highly relevant proteins to mCRPC were identified and quantified from CTCs in 100% of patients for androgen receptor (AR) and B7 homolog 3 (B7-H3), 57% of patients for trophoblast cell surface antigen-2 (TROP2), 43% of patients for prostate specific membrane antigen (PSMA), 28% of patients for programmed cell death antigen 1 (PD-L1), and 14% of patients for neuroendocrine markers chromogranin A (CHGA) and delta like ligand 3 (DLL3). Conclusions: The clear differences seen between the CTC and WBC fractions, combined with expected proteins observed in the CTC fraction, supports the successful isolation of CTCs. Together, this demonstrates a first of its kind assay able to probe multiple highly relevant proteins from CTCs that could be crucial to help minimize patient harm and better design precision therapeutics.
Innovative diagnostic approaches: Serum protein markers in renal cell carcinoma.
560 Background: In the era of precision medicine, we pursue less invasive, more powerful methods for screening, response prediction, and recurrence detection. While liquid biopsy has proven useful in other malignancies, similar diagnostic and prognostic tools for renal cell carcinoma (RCC) remain to be elucidated. We therefore aimed to investigate serum protein expression in patients before their RCC diagnosis vs. non-cancer controls to identify protein-cancer associations likely to have a role in cancer development and progression. Methods: Utilizing UK Biobank, we analyzed proteomic data in patients previously diagnosed with RCC (n=2245) vs. patients without RCC at time of serum collection who were later diagnosed (n=1225) vs. a cohort of non-cancer controls (n=44386). We estimated hazard ratios (HRs) and 95% confidence intervals (CI) using Cox proportional regression models. We investigated protein and RCC cancer-risk associations to examine the effects of reverse causality and conducted analyses to generate area under the curve (AUC) values to evaluate diagnostic performance of biomarkers. Results: We identified associations between elevated levels of tafa5, klk11, klk8, csdn, and clmp proteins and undiagnosed RCC. Highly expressed proteins in each cohort showed increased HR for cancer association (95% CI), with tafa5 exhibiting the highest HR in the treated group HR 9.7 (95%CI 6.3-12.0;p<0.00). Receiver operating characteristic curve demonstrated strong predictive capabilities: igfbp4 (AUC 0.9127;SN 0.8056;SP 0.8606), tafa5 (AUC 0.9134;SN 0.7500;SP 0.8996), tgfbr2 (AUC 0.9057;SN 0.6667;SP 0.9083), scarb2 (AUC 0.8968;SN 0.7500;SP 0.9197), nectin4 (AUC 0.9269;SN 0.7222;SP 0.9299) in the treated group. These findings indicate that specific proteomic biomarkers may have a significant association with RCC diagnosis, with high AUC values supporting their potential utility in RCC diagnosis and prognosis. Prospective validation in clinical settings is warranted. Conclusions: Our study highlights distinct protein elevations between patients presenting with RCC vs. those who were later diagnosed. Although further studies are warranted, the favorable HR, AUC, SN, and SP values for several proteins identified here underscore their potential as biomarkers for RCC diagnosis and prognosis.
Surveillance with plasma ctDNA in non-muscle invasive bladder cancer.
864 Background: Non-muscle invasive bladder cancer (NMIBC), constitutes 70% of all bladder cancer. Routine surveillance methods for detecting patients at risk of progression to muscle-invasive or metastatic disease are invasive and may delay intervention. Circulating tumor DNA (ctDNA) analysis presents a non-invasive alternative for monitoring minimal residual disease, potentially allowing for earlier detection of disease progression or recurrence. This study evaluates the role of plasma ctDNA in the early detection and monitoring of high-risk NMIBC. Methods: Eleven high-risk NMIBC patients were enrolled in this study. All patients underwent standard transurethral resection of bladder tumors (TURBT) before enrollment. Blood samples were collected prior to initiation of intravesical therapy and then every three months for two years (from January 12, 2022, to February 1, 2024). Plasma ctDNA was analyzed using Natera's Signatera, employing multiplex PCR and next-generation sequencing to detect tumor-specific mutations. Individual mutation profiles were established via whole-exome sequencing of tumor and matched normal tissue. Detection of ctDNA was compared with results from routine cystoscopy, urine cytology, and upper-tract imaging. Disease outcomes of interest included relapse, progression to muscle-invasive disease, and metastasis. Results: Of the eleven high-risk patients, one patient developed diffuse bilateral upper tract high-grade recurrence followed by metastatic disease that was preceded by positive ctDNA. Another patient was noted to have muscle-invasive disease again following the detection of ctDNA and subsequently underwent radical cystectomy. This patient eventually developed metastasis six months later. One patient elected to withdraw from the study. In our study, 20% of patients with high-grade papillary NMIBC had detectable ctDNA nine months post-diagnosis. Notably, both patients with positive ctDNA had normal findings on routine surveillance. However, they eventually progressed to stage IV urothelial carcinoma. In contrast, ctDNA was undetectable in the remaining eight patients, all of whom remained recurrent free to-date. These findings suggest ctDNA may serve as an early predictor of relapse and progression, with a number needed to test of 5 to prevent one delayed identification of disease progression. Conclusions: Plasma ctDNA analysis shows promise as a non-invasive tool for identifying NMIBC patients at risk of disease progression. Early ctDNA detection may enable more personalized treatment approaches, improving patient outcomes. Larger studies are warranted to confirm these findings and support the integration of ctDNA into standard NMIBC surveillance protocols.
Validity of heart rate measurements in wrist-based monitors across skin tones during exercise
Purpose To evaluate the accuracy of a wrist-based heart rate (HR) monitor at different exercise intensities across different skin tones. Methods Using a cross-sectional design, we compared HR measures from the wrist-based photoplethysmography Fitbit Charge 5 to the Polar H10 chest strap at rest and during the YMCA Protocol using a recumbent cycle ergometer. Participant were grouped into three skin tone categories: light (Fitzpatrick Scale Skin Types 1+2), medium (Types 3+4), and darker skin tone (Types 5+6). HR measures using the Polar chest strap during the exercise test were categorized as <40%, 40–60%, or >60% HR reserve (HRR). Absolute error in beats per minute (bpm) between the two devices was calculated for each measure. A linear mixed effects model was used to assess interaction effects between skin tone and exercise intensity, with participants as the random effect. Bland-Altman plots were used for visual analyses. Results Twenty-five participants [mean (SD): 25.8 (1.9) years old; 64% female] were included with 495 observations of simultaneous Fitbit and Polar HR recordings collected during exercise. During exercise, we observed a statistically significant interaction effect between skin tone and exercise intensity. Compared with light skin tone at <40% HRR, mean error was greater for medium skin tone at >60% HRR [mean error (95%CI): 11.8 (5.6–17.9) bpm, p<0.001] and darker skin tone at 40–60% HRR [7.6 (1.7–13.5) bpm, p = 0.011] and >60% HRR [11.7 (5.3–18.0) bpm, p<0.001]. Conclusion HR measurement error using a wrist-based device was greater with increasing exercise intensity for people with darker skin tones.
White-box methodologies for achieving robust correlations in hydrogen storage with metal-organic frameworks
Decipher genomic classifier (DGC) of early prostate cancer (EPC), and underlying transcriptomic profile (TP): American (Am) versus non-American (NA).
414 Background: Data on DGC in EPC, come predominantly from US patients (pts), revealing significant reclassification of NCCN risk Despite its global use, data among NA is scant. We aimed to analyze DGC results and TP among NA versus (vs) Am with EPC. Methods: From the DGC database (Decipher Biosciences Inc), we identified and analyzed the results (risk and TP) of Israeli (Is) vs matched Am pts with EPC. Matching was according to common NCCN clinicopathologic features (T and N stage, Gleason grade, number of adverse pathologic features). Results: Among Is pts, 692 (median age, ma, 69) had a biopsy (bx) DGC, and 115 (ma 67) a post prostatectomy (PP) DGC. Their median DGC in bx was 0.47, and PP 0.78. DGC risk was 45% low, 24% intermediate, 31% high, in bx, and 13% low, 16% intermediate, 71% high, PP. Bx DGC led to reclassification of risk in 33% of pts with clinical NCCN low-favorable intermediate risk, and 48% of pts with clinical NCCN unfavorable intermediate-high risk. Among matched Am, 103,108 (ma 68) had a bx DGC, and 40,906 (ma 65) a PP DGC. Am median DGC was 0.43 in bx, and 0.65 PP. Am DGC risk was 52% low, 20% intermediate, 28% high, in bx, and 28% low, 17% intermediate, 55% high, PP. While NCCN risk grouping was similar between Is vs matched Am (p=1.0), median DGC risk was significantly higher among Is (p<0.001), and the distribution of DGC risk groups significantly different (p=0.004 for bx, p<0.001 PP). A correlative TP analysis revealed greater overall differences of Isi vs matched Am. Significant (p<0.001) differences in bx DGC, included AR status (intact vs deficient), prostate subtype classifier (PSC, luminal differentiated, luminal proliferating, basal immune, basal neuroendocrine), PAM50 (Luminal A, Luminal B, Basal), RSI (1), Cell cycle progression (2), activated CD8, T regulatory cells, angiogenesis (Uhlik), Myeloid derived suppressor cells, Interferon response alpha hallmark, and immune 190. Significant (p<0.001) differences in PP DGC, included AR activity, p53 mutation, PSC, PAM50, SC/NE (adenocarcinoma, neuroendocrine carcinoma (3), RSI, activated CD4 and CD8, T regulatory cells, angiogenesis (Uhlik), tertiary lymphoid structure, PDL2 signature, Myeloid derived suppressor cells, and Interferon response alpha hallmark. Conclusions: In early prostate cancer, as previously reported among American pts, DGC may be an important tool for accurate patients risk assessment, leading to NCCN risk reclassification in a significant proportion, Furthermore, the present study preliminary results suggest that geographic variation DGC may exist, and correlate with differences in transcriptomic profile. 1. Torres-Roca 2009. 2. Cuzick 2011. 3. Beltran 2016.
Do tissue-based biomarkers in metastatic clear cell renal cell carcinoma perform better when derived from a metastatic site?
569 Background: Gene expression and mutation analyses in metastatic clear cell renal cell carcinoma (ccRCCs) have attempted to identify tumors that differentially respond to tyrosine kinase inhibitors (TKIs) and immunotherapy (IO) – broadly an angiogenic and an immunogenic clade. However, ccRCC is genomically heterogeneous and sequencing a single-region of a primary tumor does not necessarily represent the metastatic clone. We re-analyzed the biomarker results of the Phase III IMmotion151 trial, stratifying patients into primary-derived and metastasis-derived sequencing, to assess if metastasis-derived sequencing performed better in differentiating response to therapy. Methods: We replicated the IMmotion151 biomarker analyses on transcriptomic clusters and mutations on all patients and then stratified to 198 patients with metastasis-derived and 625 patients with primary-derived sequencing. We assessed progression-free survival (PFS) with Cox proportional hazards while controlling for IMDC risk group for atezolizumab and bevacizumab (atezo + bev) versus sunitinib based on previously-described angiogenic groupings: Cluster 1 (Angiogenic/Stromal), Cluster 2 (Angiogenic), and PBRM1 mutant tumors; and immunogenic groupings: Cluster 4 (T-effector/Proliferative), Cluster 5 (Proliferative), PBRM1 wild-type and CDKN2A -loss tumors. Results: PFS favored Sunitinib in angiogenic Cluster 2 and Clusters 1+2 when sequencing was derived from the metastatic site (HR 3.39, p=0.011; HR 2.91, p=0.005) but not the primary (HR 1.04 p=0.82; HR 1.02, p=0.88) (Table). A similar trend was observed for other angiogenic groups (Cluster 1 & PBRM1 mutant), but did not reach significance. PFS favoring atezo + bev for immunogenic groupings remained significant when derived from the primary. Conclusions: Angiogenic signatures distinctly favored sunitinib in advanced ccRCC when sequencing was derived from the metastasis but not the primary tumor. Immunogenic signatures favored atezo + bev even when derived from the primary site. A prevalent angiogenic signature throughout the primary tumor, that is now always present in the metastatic clone, may explain these results. Cox proportional hazards results for Atezo + Bev versus Sunitinib corrected for IMDC risk-group. HR >1 favors Sunitinib, HR <1 favors Atezo + Bev. Marker All patientsN= 823 for RNA-seqN= 715 patients for mutations Metastasis-Derived Sequencing OnlyN= 198 for RNA-seqN= 152 patients for mutations Primary Derived Sequencing OnlyN= 625 for RNA-seqN= 563 patients for mutations DFS- HR P- value DFS- HR P- value DFS- HR P- value Markers Favoring Angiogenic Response / Sunitinib Cluster 1- Angio/Stromal(n=98) 1.21 0.48 3.10 0.14 1.02 0.95 Cluster 2- Angio(n=245) 1.22 0.25 3.33 0.024 1.04 0.82 Cluster 1 + 2(n=343) 1.20 0.22 2.66 0.011 1.02 0.88 PBRM1 mutant(n=333) 1.05 0.73 1.72 0.13 0.86 0.33
The comparison of clinical utility between pan-cancer panel and PCa-specific panel for mCRPC.
47 Background: To compare the diagnostic efficiency of pathogenic variants and the value for clinical decision making between a pan-cancer panel and a prostate cancer (PCa)-specific panel among patients with metastatic castration-resistant PCa (mCRPC). Methods: 637 mCRPC patients underwent panel-based targeted gene sequencing (Cohort A), among which, 327 patients underwent genomic profiling with a PCa-specific panel of 50 genes and 310 patients with a pan-cancer panel of 672 genes. Furthermore, 56 patients in Cohort A received both panel-based targeted gene sequencing approaches at the same time (Cohort B). The comparisons of the diagnostic efficiencies of pathogenic variants and clinical actionable variants (CAVs) were analyzed by proportion test. Results: The diagnostic efficiency of pathogenic variants was significantly higher in pan-cancer panel group than in PCa-specific panel group either in cohort A or cohort B (p<0.0001). In cohort A, 504 of 970 genomic variants were defined as pathogenic variants among which 304 were classified as CAVs in PCa-specific panel group. In pan-cancer panel group, 1457 of 4205 genomic variants were defined as pathogenic variants among which only 304 were classified as CAVs. In cohort B, 96 of 182 genomic variants were defined as pathogenic variants among which 56 were classified as CAVs in PCa-specific panel group. In pan-cancer panel group, 260 of 788 genomic variants were defined as pathogenic variants among which only 59 were classified as CAVs. The detection rate of CAVs between the two groups was no difference either in cohort A or cohort B (p>0.05). Conclusions: The pan-cancer panel had increased detection yield of pathogenic variants and provided a rich source of data, which was helpful for genetic researches. However, the PCa-specific panel proved to be as powerful as the pan-cancer panel in the detection of CAVs for tailored treatments, which might be better in guiding clinical decision making in a cost-effectiveness and time-saving way. Thus, the NGS panels available in different sizes might be chosen depending on basic research or clinical objectives.
Navigating Industry 4.0: Leveraging additive technologies for competitive advantage in Colombian aerospace and manufacturing industries
Industry 4.0 initiatives aim to improve competitive advantage. Additive technologies are a technological innovation and have great potential in a developing country like Colombia, The study analyzes how additive technologies, strategies, and process innovation interact to generate positive results, measured by the achievement of operational effectiveness in the aerospace sector and the manufacturing industry in general. Furthermore, the study explores the integration of additive technologies within the framework of Industry 4.0, focusing on the Colombian aerospace and manufacturing sectors. It investigates how these technologies, strategies, and process innovation contribute to operational effectiveness. Data were collected using a Likert-style questionnaire, developed based on established models of innovation framework and operational effectiveness model994 responses were obtained, of which 945 were deemed usable (423 from manufacturing and 522 from aerospace sectors). The analysis involved confirmatory factor analysis (CFA) and structural equation modeling (SEM) using SPSS and AMOS software, ensuring robustness through indicators like Cronbach’s Alpha and fit indices. The study compared findings across the two sectors to highlight differences in how additive technologies influence organizational outcomes. Initial results reveal that while additive technologies significantly enhance process innovation across sectors, their direct impact on operational effectiveness is evident only in the aerospace industry. The findings underscore that the aerospace sector benefits from additive technologies due to their need for complex, high-quality, and small-batch production, emphasizing their role in fostering precision and customization. However, the lack of impact in the manufacturing context is attributed to limited strategic alignment and inadequate implementation practices. Moreover, the results indicate that process innovation is a critical mediator, facilitating the translation of technological advancements into improved operational outcomes. Despite moderate correlations between strategies and operational effectiveness in manufacturing, aerospace organizations exhibit more substantial strategic alignment due to stringent performance demands. These findings highlight the importance of fostering a culture of innovation, adapting organizational strategies, and addressing structural challenges to maximize the benefits of additive technologies. The study contributes to understanding the differential adoption of Industry 4.0 technologies in developing economies, with implications for enhancing competitiveness and sustainability in global markets.
m7G gene expression and disease risk model construction in patients with herpes zoster
Carcinoma of prostate sequencing of tumor and clinical endpoints (CAPSTONE): Clinical implications of recurrent genomic alterations in lethal prostate cancer.
220 Background: Prostate cancer (PC) is genetically heterogeneous, and genomic alterations may impact prognosis and therapy response. We created CAPSTONE, a database of lethal PC that integrates comprehensive genomic sequencing with deep clinical phenotyping to explore the clinical implications of castrate resistant prostate cancer (CRPC) evolution. Methods: PC patients underwent tissue collection (4/05-7/21) for tumor RNA-sequencing and tumor/normal whole exome sequencing (HUM00046018, HUM00048105, HUM00067928, SU2C). Sequencing was processed using Turnkey Precision Oncology. We analyzed somatic and germline mutations, gene fusions, copy number alterations, and chromosomal instability (CIN) along with transcriptomic signatures and pathways. We collected clinical data (05/21-01/22) including overall survival from time of castrate resistant prostate cancer (OScrpc) and from time of biopsy (OSb). Patients were split into discovery and validation cohorts. We used cox proportional hazard models to evaluate OS. Results: Data was available for 454 men (n=192, n=262). Median follow up from CRPC was 32.1 (IQR: 14.7-50.1) and 33.3 (IQR: 20.9-55.6) months respectively. Median age at CRPC was 66 (IQR: 60-73) and 67 (IQR: 62-72) years. Of the 1,581 recurrently altered genes (>2%), 72 had a significant (p<0.01) univariate association with OS in the discovery cohort. From these, 3 (RB1, TP53, CDKN1B) were significantly associated with OS in the validation cohort (T1). Subgroup analysis revealed AR mutations but not amplifications were associated with improved OS (T1). AR amplifications were enriched in samples with TP53 alterations (p<1.0e-3, p<1.0e-3) and high CIN (p<1.0e-3, p=8.7e-3). Finally, using discovery data, we generated a gene signature associated with OS independent of TP53, RB1, and CDKN1B and validated this signature in the validation cohort (T1). Conclusions: RB1, TP53, and CDKN1B were recurrently altered genes independently associated with worse OS in CRPC. Further, we identified a gene signature associated with poor OS in CRPC independent of these alterations. Association with OSb in CRPC. Discovery Validation (n=192) (n=262) Univariate HR (95% CI) [p] Multivariate HR (95% CI) [p] Univariate HR (95% CI) [p] Multivariate HR (95% CI) [p] OSb RB1 2.74 (1.69-4.43) [4.3e-5] 2.5 (1.47-4.24) [0.00067] 2.37 (1.53-3.68) [0.00012] 2.33 (1.49-3.63) [2e-04] TP53 2.23 (1.57-3.11) [5.9e-6] 2.55 (1.78-3.66) [3.8e-07] 1.52 (1.14-2.03) [0.0046] 1.48 (1.1-1.98) [0.0094] CDKN1B 3.39 (1.42-8.13) [0.0061] 3.46 (1.47-8.15) [0.0046] 2.47 (1.32-4.6) [0.0045] 2.86 (1.51-5.42) [0.0013] Gene signature 2.08 (1.72-2.5) [1.5e-14] 1.88 (1.56-2.28) [5e-11] 1.36 (1.17-1.57) [4.3e-05] 1.32 (1.13-1.53) [0.00035] AR amplification 1.03 (0.74-1.44) [0.86] - 1.15 (0.86-1.54) [0.34] - AR mutation 0.55 (0.3-1) [0.049] - 0.64 (0.4-1.02) [0.063] -
JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL
PURPOSE The JCCG ALL-B12 clinical trial aimed to evaluate the effectiveness of unvalidated treatment phases for pediatric ALL and develop a safety-focused treatment framework. PATIENTS AND METHODS Patients age 1-19 years with newly diagnosed B-ALL were enrolled in this study. These patients were stratified into standard-risk (SR), intermediate-risk (IR), and high-risk (HR) groups. Randomized comparisons assessed the effectiveness of vincristine (VCR)/dexamethasone pulses in the SR group, evaluated the effects of L-asparaginase (ASP) intensification in the IR group, and compared standard consolidation including block-type treatment with experimental consolidation with high-dose methotrexate (HD-MTX) intensified with VCR and ASP in the HR group. RESULTS Of 1,936 patients enrolled, 1,804 were eligible for the experimental treatment. The overall 5-year event-free survival and overall survival rates were 85.2% (95% CI, 83.5 to 86.8) and 94.3% (95% CI, 93.1 to 95.3), respectively. The cumulative incidence of relapse and postremission nonrelapse mortality was 13.2% (95% CI, 11.6 to 14.8) and 0.6% (95% CI, 0.3 to 1.0), respectively. Random assignment in the SR group showed no significant benefit from pulse therapy. In the IR group, ASP intensification had limited effects. In the HR group, standard block therapy and HD-MTX yielded equivalent outcomes. CONCLUSION The ALL-B12 trial achieved favorable outcomes in a nationwide cohort by stratifying treatment on the basis of risk and balancing treatment intensity. This study not only demonstrated that existing standard of care can be further refined but also indicated that improvement in outcomes with intensified chemotherapy has reached a plateau.
Long-term safety outcomes of <sup>177</sup> Lu-PSMA-617 in patients with prostate cancer.
TPS294 Background: Approval of [ 177 Lu]Lu-PSMA-617 ( 177 Lu-PSMA-617) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer, previously treated with androgen receptor pathway inhibitors and taxane-based chemotherapy, was based on the results of the Phase 3 VISION study (NCT03511664). It is important to further characterize long-term safety outcomes in 177 Lu-PSMA-617–treated patients, with particular regard to potential treatment-related risks. To this end, the long-term follow-up (LTFU) safety study (NCT05803941) has been established. Findings from the LTFU study will be crucial for assessing delayed toxicities for patients with PSMA-positive metastatic prostate cancer treated with 177 Lu-PSMA-617 globally. Methods: The LTFU study is a prospective, multi-center, non-EU post-authorization safety study. Patients who received ≥1 dose of 177 Lu-PSMA-617 within one of the prospective parent studies (Table 1) are eligible. Patients may enroll in the LTFU study after fulfilling the requirements of their corresponding parent study. The primary endpoint is the number and proportion of selected adverse events (AEs), including myelosuppression, xerostomia, renal failure, xerophthalmia, and second primary malignancies (eg, myelodysplastic syndrome or acute myeloid leukemia), other serious AEs, and changes in laboratory values. The secondary endpoint is the number and proportion of deaths. Following enrollment, patients will undergo assessments at baseline, and then every 6–8 months for up to 10 years after their first dose of 177 Lu-PSMA-617 or until death. At each visit, a review of selected treatment-related AEs (xerostomia, xerophthalmia, myelosuppression), any-cause AEs (renal toxicity, new diagnoses of second primary malignancies), and treatment-related serious AEs will be conducted. Physical and laboratory assessments, as well as details on concomitant medications and interventions, including anti-cancer therapies, will be collected. Patients may receive treatment with any medical intervention. Interim analyses are planned at 2 and 5 years post-study activation. Enrollment is ongoing (n=13). Clinical trial information: NCT05803941 . Parent studies of the long-term follow-up safety study. Trial Indication Phase N (all groups) ClinicalTrials.gov ID VISION (+sub-study) Post-taxane mCRPC 3 831 (+30) NCT03511664 PSMAfore Pre-taxane mCRPC 3 469 NCT04689828 PSMAddition mHSPC 3 1144 NCT04720157 177 Lu-PSMA-617 in patients with moderately or severely impaired, or normal renal function Post-taxane mCRPC 2 20 a NCT06004661 a Planned. mCRPC, metastatic castration-resistant prostate cancer; mHSPC, metastatic hormone-sensitive prostate cancer.
Enhancing machine learning performance in cardiac surgery ICU: Hyperparameter optimization with metaheuristic algorithm
The healthcare industry is generating a massive volume of data, promising a potential goldmine of information that can be extracted through machine learning (ML) techniques. The Intensive Care Unit (ICU) stands out as a focal point within hospitals and provides a rich source of data for informative analyses. This study examines the cardiac surgery ICU, where the vital topic of patient ventilation takes center stage. In other words, ventilator-supported breathing is a fundamental need within the ICU, and the limited availability of ventilators in hospitals has become a significant issue. A crucial consideration for healthcare professionals in the ICU is prioritizing patients who require ventilators immediately. To address this issue, we developed a prediction model using four ML and deep learning (DL) models—LDA, CatBoost, Artificial Neural Networks (ANN), and XGBoost—that are combined in an ensemble model. We utilized Simulated Annealing (SA) and Genetic Algorithm (GA) to tune the hyperparameters of the ML models constructing the ensemble. The results showed that our approach enhanced the sensitivity of the tuned ensemble model to 85.84%, which are better than the results of the ensemble model without hyperparameter tuning and those achieved using AutoML model. This significant improvement in model performance underscores the effectiveness of our hybrid approach in prioritizing the need for ventilators among ICU patients.
Constitutive relationships for ultra-high-performance concrete at elevated temperatures
Comorbidity burden and effectiveness of immunotherapy in patients with metastatic renal cell carcinoma.
509 Background: Comorbidities pose a challenge in the treatment of patients with cancer and present a barrier to inclusion in clinical trials. While the effect of comorbidities on the efficacy of immunotherapy (IO) has been studied in various malignancies, it remains unclear in patients with metastatic renal cell carcinoma (mRCC) treated with IO-based combinations. Methods: Data from patients with mRCC receiving IO-based combinations (IO+IO or IO+anti-vascular endothelial growth factor (VEGF)) as first-line treatment were collected from the Dana-Farber Cancer Institute and the Tom Baker Cancer Centre-University of Calgary. The comorbidity burden was assessed at baseline using the Charlson Comorbidity Index (CCI). Patients were stratified into two groups: CCI-low (≤3) or CCI-high (>3), to predict overall survival (OS) through maximally selected rank statistics. The effect of CCI on OS and time-to-treatment failure (TTF) was assessed using multivariable Cox regression models. Results: Overall, 311 patients were included. The median age was 63 years (Q1-Q3: 58-69), and most patients had clear-cell mRCC (89.7%). A total of 167 (53.7%) and 144 (46.3%) patients were treated with IO+IO and IO+anti-VEGF, respectively. The most prevalent comorbidities were cardiovascular disease (20.2%) and diabetes (18.6%). In terms of CCI, 241 (77.5%) and 70 (22.5%) patients were categorized as CCI-low and CCI-high, respectively. Median follow-up was 40.8 months (Q1-Q3: 34.4-47.2) for OS. OS (aHR: 1.89, 95% CI: 1.16-3.06, p=0.010) and TTF (aHR: 1.56, 95% CI: 1.04-2.33, p=0.029) were worse in the CCI-high group (vs. CCI-low group) after adjusting for covariates (IMDC groups, age, Karnofsky score, histology, sarcomatoid features, sites of metastases, treatment type, and nephrectomy status). Rates of all adverse events (AEs) (66% vs. 65.5%) and immune-related AEs (42.1% vs. 35.9%) were comparable between the CCI-low and CCI-high groups, respectively. Conclusions: We report for the first time that comorbidity burden is an adverse prognostic factor in patients with mRCC undergoing IO-based combinations, highlighting the need for multidisciplinary care and tailored treatment strategies in this vulnerable patient population. Interestingly, despite the observed difference in survival outcomes, the incidence and profile of AEs were similar between the high- and low-comorbidity groups, suggesting that comorbidity burden does not substantially alter the safety profile of IO-based treatments.
Estimation of overall survival in immunotherapy-treated bladder cancer using computer vision.
862 Background: Bladder cancer (BC) is a difficult and expensive cancer to treat, as lifelong care is needed. Anti-PD-1 therapies are used as a frontline treatment for BC. However, diverse response creates a need for novel methods to identify those patients that will benefit. We developed an algorithm (MIA-IO: Microscopy Image Analysis - Immunotherapy Outcome) to infer BC patient survival under anti-PD-1 immunotherapies with H&E-stained whole slide images (WSIs). Methods: A foundation model was trained on ~100k WSIs from various sources. Next, it was fine-tuned to create MIA-PDL-1, which infers PDL-1 status from H&E WSIs ( n = 1546). It was separately fine-tuned to identify tumor, stroma, necrosis and lymphocytes (training n = 2765 patches). An open-source model (CellViT) was used to identify neoplastic, inflammatory, connective, epithelial, and dead cells (training n = 190K cells). 617 features were derived from the segmentations to measure the spatial makeup of the tissues. Finally, a random survival forest (MIA-IO) was trained combining PDL-1 status, tissue/cell features, age and sex to estimate overall survival from treatment start. To develop MIA-IO, we used 331 WSIs from BC patient treated with several immunotherapies from internal trial and commercial sources (internal dataset) and 227 from a vendor as an external test set. We also evaluated MIA-IO using only patients treated with PD-1 therapies (i.e., Pembrolizumab and Nivolumab). Log-rank test was used to determine statistical significance of inferred high-risk (HR) and low-risk (LR) event times for each model. Results: The table shows survival probabilities for inferred HR and LR patient groups as stratified based on inferred death time. Survival of LR group was significantly higher than HR group for the all-immunotherapies model and for the PD-1 only therapy model in internal and external sets. Features holding greatest inference weight included texture of tumor regions and immune distributions. Cell and tissue features were found to carry the greatest estimation weight, such as texture of the tumor regions and immune distributions. Conclusions: Routine H&E biopsies may contain information prognostic of therapeutic response to immunotherapies and further study with more samples is warranted. This method is and faster than immunohistochemistry, spares additional tissue use, and may be used to select those patients that would benefit from PD-1 therapy. Survival probabilities based on algorithm stratification. Internal A Internal PD-1 External A External PD-1 Patients Train / Test ( n ) 264 / 67 157 / 39 - / 227 - / 182 MIA-IO LR / MIA-IO HR ( n ) 38 / 29 18 / 21 33 / 194 154 / 28 Overall Survival probability (LR / HR) 6-month 0.81 / 0.5 0.95 / 0.63 0.82 / 0.78 0.84 / 0.68 12-month 0.81 / 0.37 0.95 / 0.39 0.78 / 0.58 0.64 / 0.4 24-month 0.59 / 0.3 0.75 / 0.29 0.62 / 0.37 0.45 / 0.23 Log-rank test p -value 0.008 0.004 0.050 0.0182 A All patients, PD-1 PD-1 only treated cohort.
NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors.
TPS900 Background: Nectin-4 is a cell surface antigen overexpressed in multiple tumor types including urothelial cancer. Enfortumab vedotin (EV) is a first generation anti-nectin-4 antibody-drug conjugate (ADC) comprising a fully humanized antibody conjugated to an MMAE payload with heterogeneous DAR 4 and is approved in metastatic urothelial carcinoma (mUC) both as a single agent in treatment refractory disease and as first-line treatment in combination with pembrolizumab. Persistent nectin-4 expression despite progression on EV has been demonstrated in preclinical tumor models suggesting payload mediated treatment resistance. LY4052031 is a next generation anti-nectin-4 ADC, consisting of a Fc-silent IgG1 antibody conjugated to a novel topoisomerase I (TOPO 1) inhibitor camp98 (LSN3889710) via a cleavable peptide linker with improved stability and a homogeneous drug antibody ratio (DAR) of 8. LY4052031 has demonstrated robust in vivo efficacy in tumor models across a range of nectin-4 expression levels and in MMAE-resistance. Methods: NEXUS-01 (NCT06465069) is a first-in-human, open-label, multi-center, phase 1 study of LY4052031 in patients (pts) with advanced or metastatic UC or other solid tumors known to express nectin-4. LY4052031 is administered intravenously once every 3 weeks. Eligible pts have ECOG PS 0-1 with a histologic diagnosis of advanced UC, triple-negative breast, non-small cell lung, esophageal, pancreatic, gastric (Japan only), ovarian, cervical, head and neck squamous cell carcinoma, or prostate cancer. Pts must have progressed on or be ineligible for all available standard therapies, with no limit on the number of prior therapies. The study consists of phase 1a dose escalation/dose optimization and phase 1b dose expansion. Dose escalation will utilize a Bayesian optimal interval design. Additional pts will backfill previously cleared dose levels that demonstrate therapeutically relevant exposures or direct evidence of clinical activity. Optional dose optimization will involve randomized evaluation of 2 or more dose levels selected in the dose escalation phase. Dose expansion will enroll pts with UC who are EV-naïve (cohort B1) and with prior EV treatment (cohort B2), or with non-UC solid tumors (cohort C). Primary objectives are to determine the recommended phase 2 dose (RP2D) and assess the safety of LY4052031. Key secondary objectives are to evaluate the pharmacokinetic profile, immunogenicity, and antitumor activity of LY4052031 per RECIST v1.1. Nectin-4 expression and other biomarker data will be generated and correlated with clinical activity. Clinical trial information: NCT06465069 .
Barriers and facilitators of adherence to treatment interventions for COPD amongst individuals from minority ethnic communities: Meta-ethnography
Objective Numerous studies have documented the low adherence rate to treatment interventions for Chronic Obstructive Pulmonary Disease (COPD) amongst minority ethnic communities. This systematic meta-ethnographic review was performed to identify barriers and facilitators of adherence to treatment interventions (e.g., smoking cessation and pulmonary rehabilitation) of COPD in minority ethnic communities. Method This systematic meta-ethnographic review followed the approach by Noblit and Hare. Systematic searches were performed across six databases MEDLINE (OVID), EMBASE (OVID), CINAHL (EBSCO), PsycINFO (OVID), Web of Science, and Scopus from their inception until November 2023. Quality appraisal of included studies was conducted using Critical Appraisal Skills Programme (CASP) tools. Results Out of 1,329 identified citations, seven qualitative studies were included in this meta-ethnography. Using reciprocal translation, four overarching themes were developed to represent the barriers and facilitators of adherence to treatment interventions of COPD amongst minority ethnic communities: 1) positive and negative experiences affecting a person’s motivation for their care, 2) patient attitude and beliefs, 3) being able to access and attend care, and 4) the influence of communication and culture on a person’s care. Conclusion This review highlighted the barriers and facilitators of adherence to treatment interventions for COPD amongst individuals from minority ethnic communities. The key barriers include language difficulties and the inability to comprehend and communicate effectively with healthcare professionals. This demonstrates the need for further research on the impact of linguistic and cultural characteristics on adherence to treatment interventions for COPD. Addressing ethnicity-specific barriers could inform the development of tailored protocols and strategies for optimising adherence among minority ethnic communities. (PROSPERO CRD42023476187).